Log in

NASDAQ:SRRA - Sierra Oncology Stock Price, Forecast & News

$12.75
-0.50 (-3.77 %)
(As of 01/27/2020 06:00 AM ET)
Today's Range
$12.15
Now: $12.75
$13.21
50-Day Range
$0.33
MA: $0.88
$13.25
52-Week Range
$8.62
Now: $12.75
$80.40
Volume111,839 shs
Average Volume50,056 shs
Market Capitalization$123.29 million
P/E RatioN/A
Dividend YieldN/A
Beta1.31
Sierra Oncology, Inc, a clinical stage drug development company, is advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis and has demonstrated a differentiated therapeutic profile encompassing anemia-related benefits, as well as achieving substantive splenic volume reduction and constitutional symptom control. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SRRA
Previous SymbolNASDAQ:DNAI
CUSIPN/A
Phone604-558-6536

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$50.82 per share

Profitability

Net Income$-53,330,000.00

Miscellaneous

Employees79
Market Cap$123.29 million
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive SRRA News and Ratings via Email

Sign-up to receive the latest news and ratings for SRRA and its competitors with MarketBeat's FREE daily newsletter.


Sierra Oncology (NASDAQ:SRRA) Frequently Asked Questions

What is Sierra Oncology's stock symbol?

Sierra Oncology trades on the NASDAQ under the ticker symbol "SRRA."

How were Sierra Oncology's earnings last quarter?

Sierra Oncology Inc (NASDAQ:SRRA) announced its quarterly earnings results on Monday, November, 4th. The biotechnology company reported ($0.17) EPS for the quarter, beating the Zacks' consensus estimate of ($0.21) by $0.04. View Sierra Oncology's Earnings History.

When is Sierra Oncology's next earnings date?

Sierra Oncology is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Sierra Oncology.

What price target have analysts set for SRRA?

2 analysts have issued 12-month price objectives for Sierra Oncology's stock. Their forecasts range from $1.20 to $1.20. On average, they expect Sierra Oncology's share price to reach $1.20 in the next year. This suggests that the stock has a possible downside of 90.6%. View Analyst Price Targets for Sierra Oncology.

What is the consensus analysts' recommendation for Sierra Oncology?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sierra Oncology in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sierra Oncology.

Has Sierra Oncology been receiving favorable news coverage?

Media coverage about SRRA stock has been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Sierra Oncology earned a news impact score of -1.4 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Sierra Oncology.

Are investors shorting Sierra Oncology?

Sierra Oncology saw a decline in short interest during the month of January. As of January 15th, there was short interest totalling 5,510,000 shares, a decline of 10.8% from the December 31st total of 6,180,000 shares. Based on an average daily trading volume, of 2,060,000 shares, the days-to-cover ratio is currently 2.7 days. Approximately 9.5% of the company's shares are short sold. View Sierra Oncology's Current Options Chain.

Who are some of Sierra Oncology's key competitors?

What other stocks do shareholders of Sierra Oncology own?

Who are Sierra Oncology's key executives?

Sierra Oncology's management team includes the folowing people:
  • Dr. Nicholas R. Glover, Pres, CEO & Director (Age 50)
  • Dr. Barbara Klencke, Chief Devel. Officer (Age 62)
  • Dr. Mark M. Kowalski, Chief Medical Officer (Age 64)
  • Mr. Sukhi Jagpal CA, CPA, CBV, MBA, Chief Financial Officer (Age 45)
  • Dr. Keith E. Anderson Ph.D., Sr. VP of Technical Operations (Age 50)

How do I buy shares of Sierra Oncology?

Shares of SRRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Sierra Oncology's stock price today?

One share of SRRA stock can currently be purchased for approximately $12.75.

How big of a company is Sierra Oncology?

Sierra Oncology has a market capitalization of $123.29 million. The biotechnology company earns $-53,330,000.00 in net income (profit) each year or ($30.00) on an earnings per share basis. Sierra Oncology employs 79 workers across the globe.View Additional Information About Sierra Oncology.

What is Sierra Oncology's official website?

The official website for Sierra Oncology is http://www.sierraoncology.com/.

How can I contact Sierra Oncology?

Sierra Oncology's mailing address is 2150 - 885 WEST GEORGIA STREET, VANCOUVER A1, V6C 3E8. The biotechnology company can be reached via phone at 604-558-6536 or via email at [email protected]


MarketBeat Community Rating for Sierra Oncology (NASDAQ SRRA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  252 (Vote Outperform)
Underperform Votes:  235 (Vote Underperform)
Total Votes:  487
MarketBeat's community ratings are surveys of what our community members think about Sierra Oncology and other stocks. Vote "Outperform" if you believe SRRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/27/2020 by MarketBeat.com Staff

Featured Article: Treasury Bonds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel